|
Título:
|
Biological and nonbiological complex drugs for multiple sclerosis in Latin America: Regulations and risk management
|
|
Autores:
|
Carrá, A. ;
Macías Islas, M.A. ;
Tarulla, A. ;
Bichuetti, D.B. ;
Finkelsztejn, A. ;
Dadalti Fragoso, Y. ;
Árcega-Revilla, R. ;
Cárcamo Rodríguez, C. ;
Durán, J.C. ;
García Bonitto, J. ;
León, R. ;
Oehninger Gatti, C. ;
Orozco, G. ;
Vizcarra Escobar, D.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Taylor & Francis, 2019-02-22T14:55:51Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
Biological drugs and nonbiological complex drugs with expired patents are followed by biosimilars and follow-on drugs that are supposedly similar and comparable with the reference product in terms of quality, safety and efficacy. Unlike simple molecules that can be copied and reproduced, biosimilars and follow-on complex drugs are heterogeneous and need specific regulations from health and pharmacovigilance agencies. A panel of 14 Latin American experts on multiple sclerosis from nine different countries met to discuss the recommendations regarding biosimilars and follow-on complex drugs for treating multiple sclerosis. Specific measures relating to manufacturing, therapeutic equivalence assessment and pharmacovigilance reports need to be implemented before commercialization. Physical, chemical, biological and immunogenic characterizations of the new product need to be available before clinical trials start. The new product must maintain the same immunogenicity as the original. Automatic substitution of biological and complex drugs poses unacceptable risks to the patient.
|
|
En línea:
|
http://doi.org/10.1586/14737175.2015.1042456
|
